Bausch Health Reports First-Quarter 2025 Results

Bausch Health Companies Inc. released its first-quarter 2025 financial results, highlighting a 5% increase in consolidated revenues to $2.26 billion compared to the previous year. The GAAP net loss attributable to the company was $58 million, with a consolidated adjusted EBITDA of $661 million, remaining stable with prior-year levels.

The company achieved its eighth consecutive quarter of revenue and adjusted EBITDA growth, excluding Bausch + Lomb, reporting 6% and 14% increases, respectively. Bausch Health successfully refinanced $7.9 billion in April, aiming to enhance shareholder value through asset maximization and share buybacks.

Segment-specific revenue changes included a 9% increase in the Salix segment and a 28% rise in the Solta Medical segment. Meanwhile, international revenues slightly declined by 1%.